last update: November 14, 2025
Elavil is the original brand name for amitriptyline, a tricyclic antidepressant (TCA) with decades of clinical use and research behind it. While its best-known indication is major depressive disorder, amitriptyline is also widely used off-label in modern practice for conditions such as migraine prevention, neuropathic pain, fibromyalgia, tension-type headaches, and certain functional gastrointestinal disorders (for example, irritable bowel syndrome with pain-predominant symptoms). Because of its broad effect on several neurotransmitters, many patients experience benefit beyond mood—most notably improved sleep and reduced pain intensity.
Elavil has been part of psychiatric and pain medicine formularies since the early 1960s. Over time, its role has shifted: newer antidepressants often serve as first-line therapy for depression, but amitriptyline remains a valuable option when sedation is desired at bedtime, when chronic pain and insomnia coexist, or when other treatments have not provided adequate relief.
Amitriptyline primarily inhibits the reuptake of serotonin and norepinephrine, increasing their availability at synapses in the central nervous system. It also has antihistaminic and anticholinergic properties, which contribute to many of its clinical effects (for example, drowsiness, dry mouth) and some side effects. Through modulation of descending pain pathways and central sensitization, amitriptyline can reduce the amplification of pain signals, which is why it helps in neuropathic pain and headache prophylaxis. Its antihistamine effect often yields improved sleep continuity, especially at lower doses used for pain and migraine prevention.
FDA-approved: Treatment of depression in adults. While it was historically used more broadly, most current prescriptions are for off-label indications due to its analgesic and sleep-promoting benefits.
Evidence-supported off-label uses include:
Other uses mentioned historically: Some TCAs, including amitriptyline, have been studied in eating disorders and conditions like pseudobulbar affect, but they are not standard first-line options in current guidelines. Treatment of bulimia is more commonly managed with cognitive behavioral therapy and selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine, under specialist care.
Amitriptyline is not suitable for everyone. The following situations warrant avoidance or extra care:
Specific dosing should be individualized by a clinician based on indication, age, comorbidities, and concomitant medications. As a general framework:
Try to take the medicine at the same time each evening. If daytime sedation persists, consult your clinician; dividing or adjusting timing can sometimes help. Never exceed prescribed doses or modify your regimen without professional guidance.
Many side effects are dose-dependent and improve with time or dose adjustments. Report persistent or troublesome symptoms to your clinician.
Amitriptyline interacts with many medications and substances. Provide your care team and pharmacist with a complete list of prescriptions, over-the-counter medicines, and supplements.
Do not stop amitriptyline abruptly unless your clinician advises it. TCAs can produce discontinuation symptoms if stopped suddenly or reduced too quickly.
Choosing amitriptyline is a matter of balancing benefits and tolerability relative to alternatives.
Active ingredient: Amitriptyline hydrochloride. It is available as immediate-release tablets in multiple strengths. Generic options are widely available and typically used in place of branded Elavil.
While amitriptyline has been evaluated in a range of conditions over the decades, contemporary practice patterns prioritize evidence-based, guideline-supported therapies. For bulimia nervosa, psychotherapy and SSRIs lead current recommendations; tricyclics are not first-line. For pseudobulbar affect (pathological laughing and crying), dextromethorphan-quinidine is commonly used. Any off-label use of amitriptyline should follow a careful risk–benefit discussion and monitoring plan with a qualified clinician.
Patients with combinations of depression, insomnia, and chronic pain may benefit from amitriptyline’s multi-symptom reach. Those who have tried multiple standard therapies without adequate relief may also consider a trial, provided cardiac risk is assessed and drug–drug interactions are reviewed. For people who cannot tolerate activating antidepressants (for example, those that cause jitteriness), a sedating bedtime option can be advantageous—though this must be weighed against anticholinergic and cardiovascular effects.
In the United States, amitriptyline (Elavil) is a prescription-only medication. By law, it must be prescribed by a licensed clinician after an appropriate evaluation to confirm indication, rule out contraindications, and review potential interactions. Pharmacies—whether local or online—dispense amitriptyline only upon receipt of a valid prescription. Services that advertise prescription medications “without a prescription” are not compliant with U.S. regulations and may place patients at serious risk due to lack of medical oversight and quality assurance.
Legal access pathways include in-person visits with primary care or specialty clinicians, as well as telehealth evaluations through licensed providers who can determine whether amitriptyline is appropriate and issue a prescription if clinically indicated. Accredited mail‑order and online pharmacies can then dispense the medication with that prescription.
HealthSouth Rehabilitation Hospital of Petersburg offers a compliant, structured care pathway: patients can connect with licensed healthcare professionals for evaluation and, when appropriate, obtain a legitimate prescription for amitriptyline. This approach ensures medical oversight, adherence to U.S. law, and safe dispensing through regulated pharmacy partners. Any dispensing of Elavil occurs only after a clinician determines it is suitable for the patient’s specific medical needs.
Elavil (amitriptyline) is a tricyclic antidepressant used for major depressive disorder and commonly prescribed off-label for neuropathic pain, migraine prevention, tension headaches, fibromyalgia, irritable bowel syndrome pain, interstitial cystitis, and chronic insomnia.
It increases serotonin and norepinephrine by blocking their reuptake and also blocks histamine and acetylcholine receptors, which contributes to pain relief and sedation but also to side effects like dry mouth and constipation.
Sleep and nerve pain may improve in a few days to 1–2 weeks, while mood and depression symptoms typically take 2–4 weeks or longer for full effect.
For depression, many start at 25–50 mg at bedtime and increase gradually to 100–150 mg/day as tolerated; for pain, migraine, or sleep, lower doses (10–25 mg at night, titrated to 10–75 mg) are often effective; older adults usually need lower doses.
At night, because it is sedating and can cause next-day drowsiness, especially when starting or after dose increases.
Sleepiness, dry mouth, constipation, blurred vision, dizziness, weight gain, increased appetite, and orthostatic lightheadedness are common; many lessen over time.
Heart rhythm changes (QT prolongation), severe constipation or urinary retention, confusion, serotonin syndrome when combined with serotonergic drugs, seizures at high doses, and increased suicidal thoughts in young people; seek urgent care for chest pain, fainting, or severe agitation.
Avoid with MAOIs or within 14 days of MAOI use, after recent heart attack, or in untreated narrow-angle glaucoma or severe urinary retention; use caution with heart disease, seizure disorders, bipolar disorder (mania risk), liver disease, and in older adults.
Yes, weight gain and increased appetite are common due to antihistamine effects; diet, activity, and regular monitoring can help manage this.
It is sedating and often improves sleep continuity at low doses, but it can cause next-day grogginess and anticholinergic side effects, so it is not a first-line insomnia medication.
Yes, amitriptyline has strong evidence for neuropathic pain (like diabetic neuropathy, postherpetic neuralgia) and migraine prevention; effective doses are usually lower than for depression.
Taper gradually over weeks with your prescriber to minimize withdrawal symptoms (nausea, headache, insomnia, irritability) and reduce relapse risk.
Avoid MAOIs and be cautious with SSRIs/SNRIs, tramadol, linezolid, St. John’s wort (serotonin syndrome), CYP2D6 inhibitors like fluoxetine, paroxetine, bupropion (raise levels), other anticholinergics or sedatives, and QT-prolonging drugs; limit alcohol.
People with cardiac risk, age over 40–50, or on higher doses may need a baseline and follow-up EKG; check electrolytes if at risk of abnormalities; drug level monitoring is sometimes used if side effects or nonresponse occur.
It is not addictive, but sudden discontinuation can cause withdrawal-like symptoms; overdose can be dangerous, so keep it secured and follow the prescribed plan.
Avoid or minimize alcohol; combining alcohol with amitriptyline increases sedation, impairs coordination and judgment, and raises the risk of respiratory depression and overdose.
Amitriptyline is not clearly linked to birth defects but should be used only if benefits outweigh risks; use the lowest effective dose and coordinate closely with obstetric and mental health clinicians; newborns may have temporary adaptation symptoms.
Small amounts enter breast milk; many infants tolerate it, but monitor for sedation, poor feeding, or irritability; nortriptyline is often preferred during lactation due to lower anticholinergic burden; discuss with your pediatrician and prescriber.
Tell them you use amitriptyline; do not stop suddenly unless instructed; anesthesia teams adjust plans due to risks of arrhythmia, blood pressure changes, and interactions with epinephrine-containing local anesthetics and other sedatives.
Avoid driving or operating machinery until you know how you respond; many people feel drowsy or slowed, especially during the first weeks or after dose increases.
Discuss baseline EKG and careful dosing; TCAs can affect conduction and prolong QT, so many clinicians use the lowest effective dose or consider alternatives in people with significant cardiac disease.
Yes, its anticholinergic effects can precipitate angle-closure glaucoma and worsen urinary retention or BPH; avoid in untreated narrow-angle glaucoma and use caution in urinary issues.
If you miss your bedtime dose and it’s close to morning, skip it; never double up; if you take too much or someone else ingests it, seek emergency care immediately—TCA overdoses can be life-threatening.
Nortriptyline (the active metabolite of amitriptyline) is generally less sedating and less anticholinergic, making it better tolerated, especially in older adults; both work for depression and neuropathic pain, with similar efficacy at equivalent doses.
Both can prevent migraines; amitriptyline may be more sedating and helpful if insomnia coexists, while nortriptyline is often chosen when daytime drowsiness or dry mouth are problematic.
Imipramine is similarly effective for depression but is used more for nocturnal enuresis; amitriptyline tends to be more sedating and is more often used for neuropathic pain and migraine prevention.
Desipramine is the least sedating and most noradrenergic TCA, which may feel more activating and cause less weight gain; amitriptyline is usually preferred for migraine and nerve pain, while desipramine may suit patients who cannot tolerate sedation.
Doxepin is very sedating and strongly antihistaminic; low-dose doxepin is FDA-approved for insomnia, while amitriptyline is more commonly used for neuropathic pain and migraine; both can cause weight gain and anticholinergic effects.
Clomipramine is highly serotonergic and the TCA of choice for OCD; amitriptyline is more often used for pain and sleep; clomipramine has higher rates of sexual dysfunction and serotonin syndrome risk at higher doses.
Protriptyline is relatively activating with less sedation but strong anticholinergic effects and a higher tendency to cause tachycardia; it is rarely used today, while amitriptyline remains common for pain and sleep.
Trimipramine is very sedating with weaker reuptake inhibition and is sometimes chosen when insomnia dominates; amitriptyline has stronger evidence for neuropathic pain and migraine prevention.
Maprotiline (a tetracyclic related to TCAs) is strongly noradrenergic and may carry a higher seizure and rash risk; amitriptyline has broader evidence for pain conditions and is more widely used.
Amoxapine (a tetracyclic) has dopamine-blocking activity and can cause extrapyramidal symptoms and tardive dyskinesia; amitriptyline lacks those dopamine effects and is preferred for pain and sleep issues.
Amitriptyline has more robust evidence and may be more effective for nerve pain at low doses; desipramine can be tried when sedation or weight gain from amitriptyline is intolerable.
Low-dose doxepin has an FDA indication for insomnia and typically causes less next-day grogginess at those doses; amitriptyline is often used off-label for sleep but can cause anticholinergic side effects and morning hangover.
Nortriptyline is often better tolerated in older adults due to fewer anticholinergic effects and less orthostatic hypotension; amitriptyline can still be used at very low doses with careful monitoring if needed for pain or sleep.